医学
安慰剂
重组因子VIIa
穿透伤
外科
随机对照试验
输血
钝伤
麻醉
不利影响
临床终点
迟钝的
内科学
病理
替代医学
作者
Kenneth D. Boffard,Bruno Riou,Brian Warren,Peter F. M. Choong,Sandro Rizoli,Rolf Rossaint,Mads Axelsen,Yoram Kluger
出处
期刊:Journal of Trauma-injury Infection and Critical Care
[Ovid Technologies (Wolters Kluwer)]
日期:2005-07-01
卷期号:59 (1): 8-18
被引量:726
标识
DOI:10.1097/01.ta.0000171453.37949.b7
摘要
Uncontrolled bleeding is a leading cause of death in trauma. Two randomized, placebo-controlled, double-blind trials (one in blunt trauma and one in penetrating trauma) were conducted simultaneously to evaluate the efficacy and safety of recombinant factor VIIa (rFVIIa) as adjunctive therapy for control of bleeding in patients with severe blunt or penetrating trauma.Severely bleeding trauma patients were randomized to rFVIIa (200, 100, and 100 microg/kg) or placebo in addition to standard treatment. The first dose followed transfusion of the eighth red blood cell (RBC) unit, with additional doses 1 and 3 hours later. The primary endpoint for bleeding control in patients alive at 48 hours was units of RBCs transfused within 48 hours of the first dose.Among 301 patients randomized, 143 blunt trauma patients and 134 penetrating trauma patients were eligible for analysis. In blunt trauma, RBC transfusion was significantly reduced with rFVIIa relative to placebo (estimated reduction of 2.6 RBC units, p = 0.02), and the need for massive transfusion (>20 units of RBCs) was reduced (14% vs. 33% of patients; p = 0.03). In penetrating trauma, similar analyses showed trends toward rFVIIa reducing RBC transfusion (estimated reduction of 1.0 RBC units, p = 0.10) and massive transfusion (7% vs. 19%; p = 0.08). Trends toward a reduction in mortality and critical complications were observed. Adverse events including thromboembolic events were evenly distributed between treatment groups.Recombinant FVIIa resulted in a significant reduction in RBC transfusion in severe blunt trauma. Similar trends were observed in penetrating trauma. The safety of rFVIIa was established in these trauma populations within the investigated dose range.
科研通智能强力驱动
Strongly Powered by AbleSci AI